Terms: = Pancreatic cancer AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53 AND Clinical Outcome
24 results:
1. ARID1A Mutation from Targeted Next-Generation Sequencing Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract cancer.
Lee SH; Cheon J; Lee S; Kang B; Kim C; Shim HS; Park YN; Jung S; Choi SH; Choi HJ; Lee CK; Chon HJ
Cancer Res Treat; 2023 Oct; 55(4):1291-1302. PubMed ID: 37139666
[TBL] [Abstract] [Full Text] [Related]
2. Comprehensive Analysis of Expression, Prognostic Value, and Immune Infiltration for Ubiquitination-Related FBXOs in pancreatic Ductal Adenocarcinoma.
Zhang Y; Liu Q; Cui M; Wang M; Hua S; Gao J; Liao Q
Front Immunol; 2021; 12():774435. PubMed ID: 35046938
[TBL] [Abstract] [Full Text] [Related]
3. Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant tp53 Combination as an Independent Predictor of clinical outcome.
Shoucair S; Habib JR; Pu N; Kinny-Köster B; van Ooston AF; Javed AA; Lafaro KJ; He J; Wolfgang CL; Yu J
Ann Surg Oncol; 2022 Apr; 29(4):2720-2731. PubMed ID: 34792696
[TBL] [Abstract] [Full Text] [Related]
4. Early Loss of Forkhead Transcription Factor, O Subgroup, Member 1 Protein in the Development of pancreatic Ductal Adenocarcinoma.
Al-Zoughbi W; Schauer S; Pichler M; Hoefler G
Pathobiology; 2018; 85(5-6):342-347. PubMed ID: 30227407
[TBL] [Abstract] [Full Text] [Related]
5. Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations.
Ozaki T; Yu M; Yin D; Sun D; Zhu Y; Bu Y; Sang M
BMC Cancer; 2018 Mar; 18(1):309. PubMed ID: 29558908
[TBL] [Abstract] [Full Text] [Related]
6. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes.
Mueller S; Engleitner T; Maresch R; Zukowska M; Lange S; Kaltenbacher T; Konukiewitz B; Öllinger R; Zwiebel M; Strong A; Yen HY; Banerjee R; Louzada S; Fu B; Seidler B; Götzfried J; Schuck K; Hassan Z; Arbeiter A; Schönhuber N; Klein S; Veltkamp C; Friedrich M; Rad L; Barenboim M; Ziegenhain C; Hess J; Dovey OM; Eser S; Parekh S; Constantino-Casas F; de la Rosa J; Sierra MI; Fraga M; Mayerle J; Klöppel G; Cadiñanos J; Liu P; Vassiliou G; Weichert W; Steiger K; Enard W; Schmid RM; Yang F; Unger K; Schneider G; Varela I; Bradley A; Saur D; Rad R
Nature; 2018 Feb; 554(7690):62-68. PubMed ID: 29364867
[TBL] [Abstract] [Full Text] [Related]
7. Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma.
Ali AS; Grönberg M; Federspiel B; Scoazec JY; Hjortland GO; Grønbæk H; Ladekarl M; Langer SW; Welin S; Vestermark LW; Arola J; Österlund P; Knigge U; Sorbye H; Grimelius L; Janson ET
PLoS One; 2017; 12(11):e0187667. PubMed ID: 29112960
[TBL] [Abstract] [Full Text] [Related]
8. Relationship Between the Expression of O
Vitellius C; Eymerit-Morin C; Luet D; Fizanne L; Foubert F; Bertrais S; Rousselet MC; Caroli-Bosc FX
Clin Drug Investig; 2017 Jul; 37(7):669-677. PubMed ID: 28421382
[TBL] [Abstract] [Full Text] [Related]
9. Molecular, morphological and survival analysis of 177 resected pancreatic ductal adenocarcinomas (PDACs): Identification of prognostic subtypes.
Schlitter AM; Segler A; Steiger K; Michalski CW; Jäger C; Konukiewitz B; Pfarr N; Endris V; Bettstetter M; Kong B; Regel I; Kleeff J; Klöppel G; Esposito I
Sci Rep; 2017 Feb; 7():41064. PubMed ID: 28145465
[TBL] [Abstract] [Full Text] [Related]
10. pancreatic Neuroendocrine Neoplasms: Basic Biology, Current Treatment Strategies and Prospects for the Future.
Ohmoto A; Rokutan H; Yachida S
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28098761
[TBL] [Abstract] [Full Text] [Related]
11. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
Tang LH; Basturk O; Sue JJ; Klimstra DS
Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
[TBL] [Abstract] [Full Text] [Related]
12. Phenotypic characterization and clinical outcome in ampullary adenocarcinoma.
Asano E; Okano K; Oshima M; Kagawa S; Kushida Y; Munekage M; Hanazaki K; Watanabe J; Takada Y; Ikemoto T; Shimada M; Suzuki Y;
J Surg Oncol; 2016 Jul; 114(1):119-27. PubMed ID: 27132476
[TBL] [Abstract] [Full Text] [Related]
13. Prolonged survival in pancreatic cancer patients with increased regucalcin gene expression: Overexpression of regucalcin suppresses the proliferation in human pancreatic cancer MIA PaCa-2 cells in vitro.
Yamaguchi M; Osuka S; Weitzmann MN; El-Rayes BF; Shoji M; Murata T
Int J Oncol; 2016 May; 48(5):1955-64. PubMed ID: 26935290
[TBL] [Abstract] [Full Text] [Related]
14. S100 family signaling network and related proteins in pancreatic cancer (Review).
Ji YF; Huang H; Jiang F; Ni RZ; Xiao MB
Int J Mol Med; 2014 Apr; 33(4):769-76. PubMed ID: 24481067
[TBL] [Abstract] [Full Text] [Related]
15. Molecular targets of gemcitabine action: rationale for development of novel drugs and drug combinations.
Elnaggar M; Giovannetti E; Peters GJ
Curr Pharm Des; 2012; 18(19):2811-29. PubMed ID: 22390765
[TBL] [Abstract] [Full Text] [Related]
16. Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers.
Witkiewicz AK; Dasgupta A; Sammons S; Er O; Potoczek MB; Guiles F; Sotgia F; Brody JR; Mitchell EP; Lisanti MP
Cancer Biol Ther; 2010 Jul; 10(2):135-43. PubMed ID: 20431349
[TBL] [Abstract] [Full Text] [Related]
17. Survivin expression and its clinical significance in pancreatic cancer.
Lee MA; Park GS; Lee HJ; Jung JH; Kang JH; Hong YS; Lee KS; Kim DG; Kim SN
BMC Cancer; 2005 Oct; 5():127. PubMed ID: 16202147
[TBL] [Abstract] [Full Text] [Related]
18. Expression of retinoblastoma and p53 pathway-related proteins in resectable invasive ductal carcinoma of the pancreas: potential cooperative effects on clinical outcome.
Hashimoto K; Nio Y; Koike M; Itakura M; Yano S; Higami T; Maruyama R
Anticancer Res; 2005; 25(2B):1361-8. PubMed ID: 15865092
[TBL] [Abstract] [Full Text] [Related]
19. High nuclear S100A6 (Calcyclin) is significantly associated with poor survival in pancreatic cancer patients.
Vimalachandran D; Greenhalf W; Thompson C; Lüttges J; Prime W; Campbell F; Dodson A; Watson R; Crnogorac-Jurcevic T; Lemoine N; Neoptolemos J; Costello E
Cancer Res; 2005 Apr; 65(8):3218-25. PubMed ID: 15833853
[TBL] [Abstract] [Full Text] [Related]
20. Osteoclast-like giant cell tumor in mucinous cystadenocarcinoma of the pancreas: an immunohistochemical and molecular analysis.
Sedivy R; Kalipciyan M; Mazal PR; Wolf B; Wrba F; Karner-Hanusch J; Mühlbacher F; Mader RM
Cancer Detect Prev; 2005; 29(1):8-14. PubMed ID: 15734212
[TBL] [Abstract] [Full Text] [Related]
[Next]
